文献速递肝肾功能剂量调整特殊人群用药

伊沙佐米群体药代动力学分析:基于TOURMALINE-MM1等研究支持药品说明书

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

仅体表面积对第二外周室分布容积有影响,性别、年龄、种族、轻中度肾损伤和轻度肝损伤未显著影响清除率,提示无需据此调整剂量。

要点

  • 伊沙佐米系统清除率不受性别、年龄、种族、轻中度肾损伤及轻度肝损伤影响。
  • 仅体表面积与第二外周室分布容积相关,无需基于上述协变量调整剂量。
  • 口服伊沙佐米绝对生物利用度估计为58%,终末半衰期几何均值9.5天。

核心结论

  • 群体药代动力学模型显示,性别、年龄、种族、轻中度肾损伤和轻度肝损伤不影响伊沙佐米系统清除率,无需据此调整剂量。

主要发现

  • 静脉与口服数据由三室模型描述,线性分布与消除动力学,口服吸收为一阶线性吸收并含滞后时间。
  • 仅体表面积对第二外周室分布容积有影响,为最终模型唯一纳入的协变量。
  • 终末处置相半衰期几何均值为9.5天,稳态分布容积为543 L,系统清除率为1.86 L/h,口服绝对生物利用度估计为58%。

关键数值与推荐

  • 受试体表面积范围为1.2-2.7 m2,年龄范围为23-91岁。
  • 轻/中度肾损伤和轻度肝损伤未发现对系统清除率有影响,提示无需基于这些协变量调整剂量。

临床怎么用

  • 基于当前证据,轻中度肾损伤或轻度肝损伤患者、不同性别、年龄及种族患者无需因药代动力学差异调整伊沙佐米剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ixazomib is an oral proteasome inhibitor, approved in USA, Canada, Australia and Europe in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. We report a population pharmacokinetic model-based analysis for ixazomib that was pivotal in describing the clinical pharmacokinetics of ixazomib, to inform product labelling. Plasma concentration-time data were collected from 755 patients who received oral or intravenous ixazomib in once- or twice-weekly schedules in ten trials, including the global phase III TOURMALINE-MM1 study. Data were analysed using nonlinear mixed-effects modelling (NONMEM software version 7.2, ICON Development Solutions, Hanover, MD, USA). Ixazomib plasma concentrations from intravenous and oral studies were described by a three-compartment model with linear distribution and elimination kinetics, including first-order linear absorption with a lag time describing the oral dose data. Body surface area on the volume of the second peripheral compartment was the only covariate included in the final model. None of the additional covariates tested including body surface area (1.2-2.7 m2), sex, age (23-91 years), race, mild/moderate renal impairment and mild hepatic impairment were found to impact systemic clearance, suggesting that no dose adjustment is required based on these covariates. The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h. The absolute bioavailability of an oral dose was estimated to be 58%.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Gupta N, Diderichsen PM, Hanley MJ, et al. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clin Pharmacokinet. 2017. PMID: 28290121. doi:10.1007/s40262-017-0526-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。